Case Study: Pre-approval access globally

This Biotech company had an oncology orphan designation product to treat chronic myeloid leukaemia. The drug was major advancement compared to existing treatments. Based on the trial data, the company received requests for access to the drug from physicians and patients from around the world, but lacked pre-approval regulatory expertise and resources to address the expected global demand.

Read the case study to learn how Clinigen worked with 300 healthcare professionals to provide treatment to 950 patients.